Clearside Biomedical Inc expected to post a loss of 12 cents a share - Earnings Preview

Clearside Biomedical,

08/11/2024 21:39

* Clearside Biomedical Inc  CLSD.OQ   CLSD.O  is expected
to show
a fall in quarterly revenue when it reports  results on November
12 for the period ending September 30 2024
    * The Alpharetta Georgia-based  company is expected to
report a
85.7% decrease in revenue to $122.86 thousand from $859 thousand
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Clearside Biomedical Inc
is
for a loss of 12 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Clearside
Biomedical Inc is 6.00​, above​ its last closing price of $1.11.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.14       -0.13                        25.9
 Mar. 31 0001  -0.14                                    -9
 Dec. 31 2023  -0.08                  -0.08             8.6​
 Sep. 30 2023              -0.15      -0.15     Met     3.2
 ​​Jan.                    -0.14      -0.15     Missed  -5.9
 1 0001                                                 
 Mar. 31 2023  -0.14       -0.14      -0.15     Missed  -7.1​
 Jan. 1 0001   -0.13       -0.13      -0.16     Missed  -27
 Sep. 30 2022  -0.05       -0.03      -0.13     Missed  -282.4
 This summary was machine generated November 8 at 21:38 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)